Target Name: MIR1237
NCBI ID: G100302280
Review Report on MIR1237 Target / Biomarker Content of Review Report on MIR1237 Target / Biomarker
MIR1237
Other Name(s): MicroRNA 1237 | hsa-mir-1237 | hsa-miR-1237-5p | hsa-miR-1237-3p | microRNA 1237 | MIRN1237

MIR1237: A Potential Drug Target and Biomarker

MIR1237, a protein encoded by the MIR1237 gene, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study, and its potential as a drug may have significant implications for the treatment of these diseases.

The MIR1237 gene is located on chromosome 14q21 and has been shown to encode a protein with a molecular weight of approximately 41 kDa. The protein is composed of 215 amino acid residues and has a calculated pI of 9.94. MIR1237 is expressed in various tissues and cells in the body, including the brain, heart, and immune system.

One of the key features of MIR1237 is its ability to interact with various signaling molecules, including TGF-β, NF-kappa-B, and NF-kappa-B-containing proteins. TGF-β is a well-known transcription factor that regulates cell growth, differentiation, and survival, and MIR1237 has been shown to interact with TGF-β1, TGF-β2, and TGF-β3. NF-kappa-B is a signaling pathway that plays a role in inflammation, pain, and survival, and MIR1237 has been shown to interact with several NF-kappa-B-containing proteins, including NF-kappa-B1, NF-kappa-B2, and NF-kappa-B3.

MIR1237's ability to interact with these signaling molecules has led to its potential as a drug target. By targeting MIR1237, researchers may be able to disrupt its interactions with these molecules and reduce the activity of MIR1237, leading to a reduction in the growth, differentiation, and survival of cancer cells, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, MIR1237 has also been identified as a potential biomarker for several diseases. Its expression has been shown to be elevated in various tissues and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. This may suggest that MIR1237 could be used as a diagnostic tool for these diseases, as well as a target for drug development.

MIR1237's unique structure and function also make it an attractive target for research into the mechanisms of its potential drug action. Its protein has a propensity to localize to the endoplasmic reticulum (ER) and to be retained there, which may be a critical step in its regulation and function. Additionally, its ability to interact with TGF-β and NF-kappa-B signaling molecules suggests that it plays a role in the regulation of cellular processes that are important for the survival and growth of these diseases.

In conclusion, MIR1237 is a protein with great potential as a drug target and biomarker for various diseases. Its unique structure and function, as well as its ability to interact with various signaling molecules, make it an attractive target for research into the mechanisms of its potential drug action. Further studies are needed to fully understand its role in the treatment of these diseases and to develop safe and effective drugs that target MIR1237.

Protein Name: MicroRNA 1237

The "MIR1237 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1237 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1238 | MIR124-1 | MIR124-1HG | MIR124-2 | MIR124-2HG | MIR124-3 | MIR1243 | MIR1244-1 | MIR1244-2 | MIR1244-3 | MIR1245A | MIR1245B | MIR1246 | MIR1247 | MIR1248 | MIR1249 | MIR1250 | MIR1251 | MIR1252 | MIR1253 | MIR1254 | MIR1255A | MIR1255B1 | MIR1255B2 | MIR1256 | MIR1257 | MIR1258 | MIR125A | MIR125B1 | MIR125B2 | MIR126 | MIR1260A | MIR1260B | MIR1261 | MIR1262 | MIR1263 | MIR1264 | MIR1265 | MIR1266 | MIR1267 | MIR1268A | MIR1268B | MIR1269A | MIR1269B | MIR127 | MIR1270 | MIR1271 | MIR1272 | MIR1273A | MIR1273C | MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306